Evidence map›Paper›PMID 40990681›Full record

ArticleInternational journal of surgery (London, England)2026

Favorable outcome of immunotherapy use in metastatic HR+/HER2- breast cancer: a population-based cohort study.

Guansheng Zhong, Jingjing Hu, Luxin Wei, Bajin Wei, Haidong Cui, Weiyang Lou, Jinfei Ma, Wanting Shao, Lifeng Zhang, Zhijun Dai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of surgery (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Guansheng ZhongDepartment of Breast Surgery, College of Medicine, The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China.
Jingjing HuMassachusetts General Cancer Center, Boston, MA, USA.
Luxin WeiDepartment of General Surgery, The Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital), Suzhou, Jiangsu, China.
Bajin WeiDepartment of Breast Surgery, College of Medicine, The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China.
Haidong CuiDepartment of Breast Surgery, College of Medicine, The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China.
Weiyang LouDepartment of Breast Surgery, College of Medicine, The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China.
Jinfei MaDepartment of Breast Surgery, College of Medicine, The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China.
Wanting ShaoDepartment of Breast Surgery, College of Medicine, The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China.
Lifeng ZhangDepartment of General Surgery, The Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital), Suzhou, Jiangsu, China.
Zhijun DaiDepartment of Breast Surgery, College of Medicine, The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUncertainty persists regarding the efficacy of immunotherapy for patients with advanced HR+/HER2- breast cancer. We aimed to assess the survival benefit of immunotherapy in metastatic HR+/HER2- breast cancer.

methodsPatients diagnosed with de novo metastatic HR+/HER2- breast cancer from 2013-2021 were analyzed using data from the National Cancer Database. Logistic regression analysis was performed to estimate factors linked to immunotherapy use. Survival outcomes were evaluated through propensity score-matching (PSM), along with Kaplan-Meier methodology and Cox regression models.

resultsA total of 17 211 metastatic HR+/HER2- breast cancer patients were included, of whom 1571 patients receiving immunotherapy were matched 1:1 with 1571 patients not receiving immunotherapy. The immunotherapy use was more common among those with higher burden of lymph node metastasis [odds ratio (OR): 1.35; 95% confidence intervals (CIs): [1.13-1.62]; P= 0.001], and those received hormone therapy (OR: 1.21; 95% CI: [1.04-1.39]; P = 0.012) and radiotherapy (OR: 1.19; 95% CI: [1.06-1.33]; P= 0.002). Survival analysis indicated that patients who had undergone immunotherapy had a significantly improved overall survival (OS) compared with patients who had not both before (hazard ratio [HR]: 0.75; 95% CI: [0.70-0.80]; P < 0.001) and after PSM (HR: 0.77; 95% CI: [0.70-0.85]; P < 0.001). Moreover, survival benefit from usage of immunotherapy was also statistically significant in subgroups received hormone therapy (HR: 0.62; 95% CI: [0.51-0.76]; P < 0.001) or chemotherapy (HR: 0.67; 95% CI: [0.48-0.92]; P = 0.015) only.

conclusionImmunotherapy may be beneficial for the OS of patients with de novo metastatic HR+/HER2- breast cancer. Our data may provide clues for the integration of immunotherapy into future clinical treatment strategies.

Indexed as

Breast NeoplasmsImmunotherapyAdultAgedCohort StudiesErb-b2 Receptor Tyrosine KinasesFemaleHumansLymphatic MetastasisMiddle AgedPropensity ScoreReceptors, EstrogenRetrospective StudiesTreatment OutcomeERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, Estrogenbreast cancerHR+HER2−metastasisNCDBsurvival

Identifiers

PMID40990681
PMCPMC12825736

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.